Moldova Pharmaceuticals and Healthcare Report Q2 2009
- ID: 940939
- April 2009
- Region: Moldova
- 54 Pages
- Business Monitor International
Moldova Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Moldova's pharmaceuticals and healthcare industry.
Moldova’s pharmaceutical market stood at US$206mn in 2008 and is forecast to grow to US$309mn in 2013. This represents a compound annual growth rate (CAGR) of 14.08%. The country has seen its healthcare budget almost triple since the introduction of obligatory health insurance in 2003, and in the coming years, growth in the drug market will be driven by the continuing modernization of the health sector. In 2009, for example, the health insurance budget increased by 30% compared to 2008. In February 2009, three legislative amendments were adopted by Molodova’s parliament, giving low income families the right to free health insurance. Families that already receive social assistance will be given full insurance coverage, as part of the government’s 2008-2017 plan to increase access to health services.
Presently, there are 17 categories of people who receive free health insurance, this includes – children, retirees, the disabled, students, pregnant women and the unemployed. It is estimated by the Commission for Social Protection, Health and Family that the extra coverage for low-income families will cost around MDL1mn (US$93,457).
Moldova has stated its ambitions to reduce its reliance on pharmaceutical imports by boosting its domestic industry. Similar to Belarus's nationalistic strategy and the backing of Belbiopharm, the Moldovan government has backed state-owned Farmaco to pioneer the development of the domestic industry. In February 2008, President Vladimir Voronin took part in the launching ceremony of a new automatic production line at Farmaco which will expand the company's product range by 40%. President Voronin noted the importance of the event, not only for Farmaco, but for the pharmaceutical field in general.
However, Moldova remains near the foot of the Business Environment Ranking for the Emerging Europe region. Key problems include the small overall market size, a declining population, and insufficient health financing. Although Moldova is making serious improvements to its health sector and is increasing access to drugs, it is believed it will remain around the bottom of the rankings for the foreseeable future. SHOW LESS READ MORE >
Moldova Pharmaceuticals And Healthcare Industry SWOT
Pharmaceutical Business Environment Ratings
Table: Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Moldova - Market Summary
Intellectual Property Rights
Table: Republic of Moldova - Out-of-pocket Payments for Healthcare
International Trade Agreements
Table: Republic of Moldova - Top 10 Causes of Death .
Table: Republic of Moldova – Leading Causes Of Morbidity As % of Total Disease Burden
Republic of Moldova - Acute Tuberculosis Morbidity ('000 population)
Table: Republic of Moldova - Voluntary Health Insurance Indicators
Compulsory Health Insurance
Table: Republic of Moldova – Social Health Insurance (SHI) Contributions By Source (As % Of Total) .
Table: Republic of Moldova – The Flat-Rate Contributions for Self-Insured/Per Capita Budget Contributions For The Unemployed.
Research and Development
Industry Forecast Scenario
Overall Market Forecast
Table: Moldova – Drug Market Expenditure, 2003-2013 (MDLmn unless otherwise stated)
Key Growth Factors – Industry
Table: Moldova – Health Expenditure, 2003-2013 (MDLmn unless otherwise stated)
Prescription Drug Market Forecast.
Table: Moldova - Prescription Drug Market, 2003-2013 (MDLmn unless otherwise stated)
Patented Drug Market Forecast
Table: Moldova - Patented Drug Market, 2003-2013
Generic Drug Market Forecast
Table: Moldova – Generic Drug Market, 2003-2013.
OTC Drug Market Forecast.
Table: Moldova – OTC Market, 2003-2013 (MDLmn unless otherwise stated).
Pharmaceutical Export/Import Forecast
Table: Moldova – Pharmaceutical Trade Balance, 2003-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Moldova – Other Health Indicators, 2003-2013.
Key Risks To BMI’s Forecasts
Table: Republic Of Moldova – Top 10 Local Manufacturers (H107)
Table: Republic Of Moldova – Top 10 Manufacturers By Value
Table: Republic of Moldova – Top 10 Trade, INNs/Combinations And ATC Groups As Percentages Of Total Market Value (H108)
BMI Forecast Modelling.
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology .
Table: Pharmaceutical Business Environment Indicators .
Table: Weighting Of Components